Alex Slanix Paul 4

What Happened

• Alex Slanix Paul, a director of ProMIS Neurosciences Inc. (PMN), received two derivative awards on May 20, 2026 totaling 16,500 shares (5,500 and 11,000) at $0.00 per share. The awards are grants of derivative securities (options/awards) and not open-market purchases or sales; there was no cash paid and no immediate sale.

Key Details

• Transaction date: May 20, 2026; Form 4 filed May 22, 2026 (filed within the normal two-business-day window).
• Grants: 5,500 and 11,000 derivative shares, $0.00 per share; total awarded = 16,500 shares (no immediate cash value reported).
• Vesting: One award vests in full on May 20, 2027, subject to continued Board service; the other award had 25% vest upon grant with the remaining shares vesting ratably over 36 months, subject to continued Board service.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Transaction code: A = grant/award (derivative). No 10b5-1 plan, tax withholding, or late filing flag was indicated in the supplied data.

Context

• These are time‑based derivative awards subject to vesting; they do not represent an immediate purchase or sale of common stock. Such grants are routine compensation for directors and are intended as long-term incentive, not an immediate market transaction.